Lumateperone and lemborexant March 9, 2020 From The Carlat Psychiatry Report Issue Links: Learning Objectives | Editorial Information | PDF of Issue The antipsychotic lumateperone (Caplyta) and the hypnotic lemborexant (Dayvigo) are the newest in their class. Both of them claim to improve on the safety of older medications, and we look at the data to see how those claims hold up.Read More
General Psychiatry An Off-Label Guide to Gabapentin | Anxiety, Sleep, Addiction, Pain, & MoreRead More
General PsychiatryPsychoanalysis Looks InwardThe Holmes Report looked at racial, social, and economic biases in psychoanalysis. Beverly Stoute, MD, shares the findings.Listen now
How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered PractitionersMay 24, 2024
How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered PractitionersMay 24, 2024
How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered PractitionersMay 24, 2024